Sulindac Confers High Level Ischemic Protection to the Heart Through Late Preconditioning Mechanisms

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2009 Nov 4

PMID 19884509

Citations 11

Authors

Ian Moench

Howard Prentice

Zach Rickaway

Herbert Weissbach

Affiliations

Soon will be listed here.

Abstract

We have recently shown that sulindac, an anti-inflammatory drug, enhances the killing of cancer cells, but not normal cells, under conditions of oxidative stress, by mechanisms unrelated to its cyclooxygenase (COX) inhibition. To further study the protective effect of sulindac on cells exposed to oxidative stress, we have investigated the effect of sulindac on rat cardiac myocytes subjected to hypoxia/reoxygenation, as well as in a Langendorff model of myocardial ischemia. Low levels of sulindac could protect cardiac myocytes against cell death due to hypoxia/reoxygenation. In the Langendorff model sulindac provided significant protection against cell death, when the drug was fed to the animals before the removal of the heart for the Langendorff procedure. The results indicate that the primary protective effect of sulindac in these experiments does not involve its role as a COX inhibitor. Numerous signaling pathways have been implicated in myocardial protective mechanisms, many of which involve fluctuations in reactive oxygen species (ROS) levels. The results suggest that low levels of sulindac can induce a preconditioning response, triggered by ROS, to protect cardiac tissues against oxidative damage. Blocking of preconditioning pathways by administration of the PKC blocker chelerythrine abrogated the ischemic protection afforded by sulindac. Secondly, after feeding of sulindac, two end-effectors of preconditioning, inducible nitric oxide synthase and heat shock protein 27, were found to be markedly induced in the heart, dependent on PKC. These results suggest that sulindac may have therapeutic potential as a preconditioning agent.

Citing Articles

Lifespan benefits for the combination of rapamycin plus acarbose and for captopril in genetically heterogeneous mice.

Strong R, Miller R, Cheng C, Nelson J, Gelfond J, Allani S Aging Cell. 2022; 21(12):e13724.

PMID: 36179270 PMC: 9741502. DOI: 10.1111/acel.13724.

A novel sulindac derivative protects against oxidative damage by a cyclooxygenase-independent mechanism.

Allani S, Rayala R, Rivera O, Prentice H, Chen X, Ramirez-Alcantara V J Pharmacol Exp Ther. 2022; 382(2).

PMID: 35680377 PMC: 9341458. DOI: 10.1124/jpet.122.001086.

Myocardial and mitochondrial effects of the anhydrase carbonic inhibitor ethoxzolamide in ischemia-reperfusion.

Ciocci Pardo A, Arbelaez L, Fantinelli J, Alvarez B, Mosca S, Swenson E Physiol Rep. 2021; 9(22):e15093.

PMID: 34806317 PMC: 8606860. DOI: 10.14814/phy2.15093.

Identification of activators of methionine sulfoxide reductases A and B.

Cudic P, Joshi N, Sagher D, Williams B, Stawikowski M, Weissbach H Biochem Biophys Res Commun. 2016; 469(4):863-7.

PMID: 26718410 PMC: 4724238. DOI: 10.1016/j.bbrc.2015.12.077.

Sulindac for stroke treatment: neuroprotective mechanism and therapy.

Modi J, Prentice H, Wu J Neural Regen Res. 2015; 9(23):2023-5.

PMID: 25657710 PMC: 4316457. DOI: 10.4103/1673-5374.147919.

References

Hattori R, Otani H, Maulik N, Das D . Pharmacological preconditioning with resveratrol: role of nitric oxide. Am J Physiol Heart Circ Physiol. 2002; 282(6):H1988-95. DOI: 10.1152/ajpheart.01012.2001. View

Moskovitz J, Williams W, Requena J, Berlett B, Stadtman E . Methionine sulfoxide reductase (MsrA) is a regulator of antioxidant defense and lifespan in mammals. Proc Natl Acad Sci U S A. 2001; 98(23):12920-5. PMC: 60800. DOI: 10.1073/pnas.231472998. View

Dawn B, Guo Y, Rezazadeh A, Wang O, Stein A, Hunt G . Tumor necrosis factor-alpha does not modulate ischemia/reperfusion injury in naïve myocardium but is essential for the development of late preconditioning. J Mol Cell Cardiol. 2004; 37(1):51-61. DOI: 10.1016/j.yjmcc.2004.03.012. View

Jones S, Bolli R . The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol. 2005; 40(1):16-23. DOI: 10.1016/j.yjmcc.2005.09.011. View

Hausenloy D, Yellon D . Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res. 2006; 70(2):240-53. DOI: 10.1016/j.cardiores.2006.01.017. View

Guo Y, Jones W, Xuan Y, Tang X, Bao W, Wu W . The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci U S A. 1999; 96(20):11507-12. PMC: 18064. DOI: 10.1073/pnas.96.20.11507. View

West M, Rokosh G, Obal D, Velayutham M, Xuan Y, Hill B . Cardiac myocyte-specific expression of inducible nitric oxide synthase protects against ischemia/reperfusion injury by preventing mitochondrial permeability transition. Circulation. 2008; 118(19):1970-8. PMC: 2763350. DOI: 10.1161/CIRCULATIONAHA.108.791533. View

Shinmura K, Bolli R, Liu S, Tang X, Kodani E, Xuan Y . Aldose reductase is an obligatory mediator of the late phase of ischemic preconditioning. Circ Res. 2002; 91(3):240-6. DOI: 10.1161/01.res.0000029970.97247.57. View

Venkatakrishnan C, Tewari A, Moldovan L, Cardounel A, Zweier J, Kuppusamy P . Heat shock protects cardiac cells from doxorubicin-induced toxicity by activating p38 MAPK and phosphorylation of small heat shock protein 27. Am J Physiol Heart Circ Physiol. 2006; 291(6):H2680-91. DOI: 10.1152/ajpheart.00395.2006. View

10.

Raval A, Dave K, Mochly-Rosen D, Sick T, Perez-Pinzon M . Epsilon PKC is required for the induction of tolerance by ischemic and NMDA-mediated preconditioning in the organotypic hippocampal slice. J Neurosci. 2003; 23(2):384-91. PMC: 6741876. View

11.

Marais E, Genade S, Salie R, Huisamen B, Maritz S, Moolman J . The temporal relationship between p38 MAPK and HSP27 activation in ischaemic and pharmacological preconditioning. Basic Res Cardiol. 2004; 100(1):35-47. DOI: 10.1007/s00395-004-0495-7. View

12.

Marchetti M, Resnick L, Gamliel E, Kesaraju S, Weissbach H, Binninger D . Sulindac enhances the killing of cancer cells exposed to oxidative stress. PLoS One. 2009; 4(6):e5804. PMC: 2686156. DOI: 10.1371/journal.pone.0005804. View

13.

Xuan Y, Tang X, Qiu Y, Banerjee S, Takano H, Han H . Biphasic response of cardiac NO synthase isoforms to ischemic preconditioning in conscious rabbits. Am J Physiol Heart Circ Physiol. 2000; 279(5):H2360-71. DOI: 10.1152/ajpheart.2000.279.5.H2360. View

14.

Resnick L, Rabinovitz H, Binninger D, Marchetti M, Weissbach H . Topical sulindac combined with hydrogen peroxide in the treatment of actinic keratoses. J Drugs Dermatol. 2009; 8(1):29-32. View

15.

Akita Y, Otani H, Matsuhisa S, Kyoi S, Enoki C, Hattori R . Exercise-induced activation of cardiac sympathetic nerve triggers cardioprotection via redox-sensitive activation of eNOS and upregulation of iNOS. Am J Physiol Heart Circ Physiol. 2007; 292(5):H2051-9. DOI: 10.1152/ajpheart.01102.2006. View

16.

Gross E, Hsu A, Gross G . Acute aspirin treatment abolishes, whereas acute ibuprofen treatment enhances morphine-induced cardioprotection: role of 12-lipoxygenase. J Pharmacol Exp Ther. 2004; 310(1):185-91. DOI: 10.1124/jpet.103.064667. View

17.

Yoshida T, Maulik N, Engelman R, Ho Y, Das D . Targeted disruption of the mouse Sod I gene makes the hearts vulnerable to ischemic reperfusion injury. Circ Res. 2000; 86(3):264-9. DOI: 10.1161/01.res.86.3.264. View

18.

Ciolino H, Bass S, MacDonald C, Cheng R, Yeh G . Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells. Int J Cancer. 2007; 122(5):990-8. DOI: 10.1002/ijc.23218. View

19.

Hennekens C, Borzak S . Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease. J Cardiovasc Pharmacol Ther. 2008; 13(1):41-50. DOI: 10.1177/1074248407312990. View

20.

Gross G . Role of opioids in acute and delayed preconditioning. J Mol Cell Cardiol. 2003; 35(7):709-18. DOI: 10.1016/s0022-2828(03)00135-4. View